A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Exclusion Criteria

• •1. Subjects with other eosinophilic-related diseases;
• •2. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
• •3. Life-threatening EGPA within 3 months prior to randomization;
• •4. Malignancy history within 5 years prior to randomization;
• •5. Immunodeficiency;
• •6. Uncontrolled hypertension；
• •7. Uncontrolled cerebrovascular and cardiovascular disease;
• •8. parasitic infection within 6 months prior to randomization;
• •9. Active infectious disease requiring clinical treatment within 4 weeks prior to randomization;
• •10. Subjects with a dose of oral prednisone of \>50 mg/day within 4 weeks prior to randomization;
• •11. Oral or intravenous cyclophosphamide therapy within 4 weeks prior to randomization;
• •12. Intravenous or subcutaneous immunoglobulin within 12 weeks prior to randomization;
• •13. Biological agents or TH2 cytokine inhibitors used within 12 weeks prior to randomization or within 5 half-lives of the drug;
• •14. Rituximab used within 6 months prior to randomization；
• •15. Surgical plans that might affect the evaluation;
• •16. Significant laboratory abnormalities；
• •17. Prolonged QTc interval or other electrocardiogram abnormalities with significant safety risk at screening;
• •18. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;
• •19. Subjects participated another clinical study and received active drug within 30 days or 5 half-lives of the drug prior to screening;
• •20. Subjects is pregnant, lactating, or planning to be pregnant;
• •21. Subjects have a known history of hypersensitivity or intolerance to anti-IL-5 mabs or other biological agents or previous failure of IL-5/IL-5R therapy;
• •22. Other conditions unsuitable for participation in the study per investigator judgement.